Advertisement
Advertisement

PVLA

PVLA logo

Palvella Therapeutics, Inc. Common Stock

76.79
USD
Sponsored
-5.11
-6.24%
Jan 30, 16:00 UTC -5
Closed
exchange

After-Market

76.75

-0.04
-0.05%

PVLA Earnings Reports

Positive Surprise Ratio

PVLA beat 22 of 36 last estimates.

61%

Next Report

Date of Next Report
Mar 30, 2026
Estimate for Q4 25 (Revenue/ EPS)
--
/
-$0.93
Implied change from Q3 25 (Revenue/ EPS)
--
/
-9.71%
Implied change from Q4 24 (Revenue/ EPS)
--
/
-65.81%

Palvella Therapeutics, Inc. Common Stock earnings per share and revenue

On Nov 11, 2025, PVLA reported earnings of -1.03 USD per share (EPS) for Q3 25, missing the estimate of -0.85 USD, resulting in a -20.45% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -3.04% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 17 analysts forecast an EPS of -0.93 USD, with revenue projected to reach -- USD, implying an decrease of -9.71% EPS, and increase of 0.00% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Nurix Therapeutics, Inc. Common stock
Report Date
Jan 28, 2026 For Q4 25
Estimate
-$0.88
Actual
-$0.82
Surprise
+7.66%
logo
Regeneron Pharmaceuticals Inc
Report Date
Jan 30, 2026 For Q4 25
Estimate
$10.84
Actual
$11.44
Surprise
+5.52%
FAQ
For Q3 2025, Palvella Therapeutics, Inc. Common Stock reported EPS of -$1.03, missing estimates by -20.45%, and revenue of $0.00, 0% as expectations.
The stock price moved down -3.04%, changed from $80.29 before the earnings release to $77.85 the day after.
The next earning report is scheduled for Mar 30, 2026.
Based on 17 analysts, Palvella Therapeutics, Inc. Common Stock is expected to report EPS of -$0.93 and revenue of -- for Q4 2025.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement